Norvir Exclusivity Is Safe; NIH Says "March-In" Test Is Availability, Not Price
Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.
Abbott has met the requirements of the Bayh/Dole Act, NIH declares. "March-in" rights are not the right way to address drug pricing, agency says: that is up to Congress.